GlassScriptPhysician profile
Kealan D Oneill
NPI 1003357195
$2,943.83
in general payments reported to CMS, 2019-2025
18 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.63 · 2020: $182 · 2021: $502 · 2022: $511 · 2023: $557 · 2024: $580 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,205.34 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $354.34 | 2020-2023 | Livalo, Seglentis |
| Amgen INC. | $317.55 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $276.87 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $147.74 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $143.91 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $120.80 | 2019-2025 | |
| Lilly USA, LLC | $89.37 | 2020-2024 | Zepbound, Mounjaro |
| Antares Pharma, INC. | $59.54 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Exact Sciences Corporation | $49.94 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $34.10 | 2022 | |
| Idorsia Pharmaceuticals US INC | $28.73 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $27.92 | 2020-2022 | |
| Tolmar, INC. | $20.84 | 2025 | Jatenzo |
| Gilead Sciences, INC. | $18.71 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.68 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.29 | 2025 | Voquezna |
| Medtronic, INC. | $13.16 | 2024 | Closurefast |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kealan Oneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.